Abbott Laboratories has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes
What makes this test so different is where it can be used: outside the four walls of a traditional hospital such as in the physicians’ office or urgent care clinics.
The new Abbott ID NOW COVID-19 test runs on Abbott’s ID NOWTM platform—a lightweight box (6.6 pounds and the size of a small toaster) that can sit in a variety of locations.
— Abbott (@AbbottNews) March 30, 2020
Because of its small size, it can be used in more non-traditional places where people can have their results in a matter of minutes, bringing an alternate testing technology to combat the novel coronavirus.
Abbott is ramping up production to deliver 50,000 ID NOW COVID-19 tests per day to the U.S. healthcare system.
Testing remains a crucial step in controlling the novel COVID-19 pandemic. Continuing to supply healthcare providers with new technologies to help curb the spread of infection is a top priority for public health officials and healthcare providers.
Taking molecular testing to the front lines
Molecular point-of-care testing for COVID-19 offers healthcare workers rapid results in more settings where people show up for care. Molecular testing technologies help detect the presence of a virus by identifying a small section of the virus’ genome, then amplifying that portion until there’s enough for detection. This process can cut testing wait time from hours, if not days, to as little as five minutes for positive results and 13 minutes for negative results.